Publications by authors named "David Covert"

Claim this Profile
P
Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2.
Matthew L Fidler, Abayomi Ogundele, David Covert, Ramesh Sarangapani

J Pharmacokinet Pharmacodyn· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resource Utilization Among Glaucoma Patients in the UK Treated with Beta-Blocker and Non-Beta-Blocker Adjunctive Therapy: A Retrospective Cohort Analysis.
Ananth Viswanathan, Claudio Spera, Anmol Mullins, David Covert, Judit Banhazi

Adv Ther· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An updated estimate of costs of endophthalmitis following cataract surgery among Medicare patients: 2010-2014.
Jordana K Schmier, Carolyn K Hulme-Lowe, David W Covert, Edmund C Lau

Clin Ophthalmol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment costs of cystoid macular edema among patients following cataract surgery.
Jordana K Schmier, David W Covert, Carolyn K Hulme-Lowe, Anmol Mullins, Emmanuel M Mahlis

Clin Ophthalmol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs.
Jordana K Schmier, Carolyn K Hulme-Lowe, David W Covert

Clin Ophthalmol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient race, reported problems in using glaucoma medications, and adherence.
Betsy Sleath, Susan J Blalock, David Covert, Asheley Cockrell Skinner, Kelly W Muir

ISRN Ophthalmol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical service encounters and payments associated with topical adjunctive therapy use of timolol for glaucoma.
Jordana K Schmier, David W Covert, Edmund C Lau

Clin Drug Investig· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns and costs associated with progression of age-related macular degeneration.
Jordana K Schmier, David W Covert, Edmund C Lau

Am J Ophthalmol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a short version of the glaucoma medication self-efficacy questionnaire.
Betsy Sleath, Susan J Blalock, Jennifer L Stone, Asheley Cockrell Skinner, David Covert

Br J Ophthalmol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A video study of drop instillation in both glaucoma and retina patients with visual impairment.
Amy L Hennessy, Joanne Katz, David Covert, Colleen A Kelly, Eric P Suan

Am J Ophthalmol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity.
Betsy Sleath, Susan Blalock, David Covert, Jennifer L Stone, Asheley Cockrell Skinner

Ophthalmology· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: a Canadian population-based analysis.
Michael Iskedjian, David W Covert, John H Walker

Patient· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-year treatment costs among new initiators of topical prostaglandin analogs.
Jordana K Schmier, David W Covert, Alan L Robin

Clin Ophthalmol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of respondents with glaucoma and dry eye in a national panel survey.
Jordana K Schmier, David W Covert

Clin Ophthalmol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss.
Amy L Hennessy, Joanne Katz, David Covert, Colleen Protzko, Alan L Robin

Ophthalmology· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008.
Jordana K Schmier, David W Covert, Alan L Robin

Curr Med Res Opin· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs.
Jordana K Schmier, Edmund C Lau, David W Covert

Clin Ophthalmol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results.
Jordana K Schmier, David W Covert

Clin Ophthalmol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of visual impairment on service and device use by individuals with diabetic retinopathy.
Jordana K Schmier, David W Covert, G Philip Matthews, Z Nicholas Zakov

Disabil Rehabil· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in annual medicare expenditures for glaucoma surgical procedures from 1997 to 2006.
Jordana K Schmier, David W Covert, Edmund C Lau, Alan L Robin

Arch Ophthalmol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An objective evaluation of eyedrop instillation in patients with glaucoma.
Jennifer L Stone, Alan L Robin, Gary D Novack, David W Covert, Gerald D Cagle

Arch Ophthalmol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-year treatment patterns among new initiators of topical prostaglandin analogs.
Jordana K Schmier, David W Covert, Alan L Robin

Curr Med Res Opin· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self-reported prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients.
Betsy Sleath, Rex Ballinger, David Covert, Alan L Robin, John E Byrd

Am J Geriatr Pharmacother· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medicare expenditures associated with diabetes and diabetic retinopathy.
Jordana K Schmier, David W Covert, Edmund C Lau, G Philip Matthews

Retina· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported barriers to glaucoma medication access, use, and adherence in southern India.
Betsy L Sleath, R Krishnadas, Minhee Cho, Alan L Robin, Rakhi Mehta, David Covert

Indian J Ophthalmol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis